Navigation Links
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
Date:9/5/2012

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. R333 is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus erythematosus (DLE, or lupus of the skin). 

"R343 and R333 are leading the way in a substantial lineup of proprietary product candidates in Rigel's pipeline," said James M. Gower, chairman and chief executive officer of Rigel.  "In addition to fostamatinib, which is in Phase 3 with our partner AstraZeneca, we now have two products in Phase 2 clinical studies and several more in, or preparing to enter, the clinic. Rigel continues to demonstrate its R&D productivity," he added.

Phase 2 Study of R343, an inhaled SYK inhibitor
Approximately 270 adults with allergic asthma will be randomized into the three arms of this Phase 2 clinical study of R343, called SITAR (SYK Inhibition for Treatment of Asthma with R343), for eight weeks of treatment with either of two different doses of the study agent or placebo. The primary endpoint of this double-blind, multi-center study will be the measurement of each patient's change in FEV1 (the maximum amount of air a person can forcefully exhale in one second) from baseline to dosing completion.  Rigel will be using the 3M™ Taper Dry Powder Inhaler device for this trial. Rigel expects to complete this study in 2013.

Phase 2 Study of R333, a topical JAK/SYK inhibitor
In this Phase 2, double-blind, multi-center study, called SKINDLE (SYK Kinase Inhibition for DLE), more than 50 patients with active discoid skin lesions from DLE or Systemic Lupus Eryth
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... report to their offering. This independent ... 130 patient groups with an interest in diabetes on ... of the pharma industry as a whole) in 2014. ...
(Date:4/17/2015)... 16, 2015 Research and Markets ... the "The Corporate Reputation of Pharma - ... " report to their offering. ... is now in its fourth edition. This report ... 2015). For each annual Corporate Reputation report, the ...
(Date:4/17/2015)... 2015 Sigma-Aldrich Corporation (NASDAQ: ... High Technology company, today announced the opening of ... and state-of-the-art Cell Culture Technical Center in Singapore.  ... provide customized support to meet customer needs, leveraging ... "Our new Technical Center will significantly enhance our ...
Breaking Medicine Technology:Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5
... YORK, Oct. 25, 2011 Reportlinker.com ... report is available in its catalogue: ... System Disorders Therapeutics Market to 2017 ... and Schizophrenia Accounted for Half the ...
... BOSTON, Oct. 25, 2011 PAREXEL International ... leading global biopharmaceutical services provider, today announced ... to provide biopharmaceutical companies with dedicated support ... has fully integrated its commercialization services to ...
Cached Medicine Technology:Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value 2PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value 3PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value 4PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value 5
(Date:4/18/2015)... 18, 2015 Patients who undergo radiation ... mesothelioma later in life, but the disease is likely ... is unrelated to radiation. Surviving Mesothelioma has just posted ... Click here to read it now. , ... cases of 45 patients who had both a hematologic ...
(Date:4/18/2015)... 18, 2015 Aureus Medical Group ... including physical therapy jobs, has announced that it ... Carolina Physical Therapy Association Annual Conference to be ... in Greenville, SC. , The SCAPTA Annual ... with products and services. , Representatives from ...
(Date:4/17/2015)... April 17, 2015 John Evans, a ... on the Patio from 2 p.m. to 3 p.m. ... at 1320 Executive Ct. in Pekin, Illinois, serves older ... need some help to maintain their independence. , Becky ... tropical treats will be served during the luau. , ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital at ... were all selected as Top Workplaces in Tampa Bay. ... is ranked number one for large businesses according to ... in partnership with an independent research firm. Florida Hospital ... opened in October of 2012 with a vision of ...
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
Breaking Medicine News(10 mins):Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:House Representatives Introduce Bill to Fight Genetic Disease 2
... The deterioration of Hong Kong’s air quality has resulted in ... ,The deterioration of Hong Kong’s air quality ... with breathing problems. , , ,Researchers at ... such as sulphur dioxide, nitrogen dioxide and ozone of about ...
... The U.S. Food and Drug Administration (FDA) have approved a ... meats. This approval was given last month.// , ... Listeria. The approved spray is a combination of viruses that ... these foods before packaging and distribution. ,This virus ...
... A new study in the latest issue of the New ... help heart attack survivors. However more research is needed to ... effect of stem cells given to survivors of heart attacks ... hearts. Researchers looked at whether stem cells could repair the ...
... soothing guilt-free chocolate body wrap or deep relaxation with Indian ... a few years ago. ,But they are ... chattering classes, who seek a pampered lifestyle in the country's ... present to spend a few very feminine hours in one ...
... U.S. Food and Drug Administration on Wednesday reported having ... patch, cautioning users about the higher risk of blood ... Johnson’s commissioned study revealed that drug users faced two ... lungs compared to women taking traditional birth-control pills. ...
... experts, 80% of people suffering from severe chronic lung ... aware of it.// ,Chronic Bronchitis and Emphysema constitute ... to lung tissue by smoking can lead to the ... ,Professor Robert West, director of tobacco studies at ...
Cached Medicine News:Health News:Luxury Spas Ride Boom in Wellness Industry in Poland 2Health News:Contraceptive Patch Carries Risk of Blood clots 2Health News:80% of lung disease remains ‘undiagnosed’. 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: